# DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1

DOI: 10.1073/pnas.0708659104
Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18157-62.

| # | Paper | IF | Citations |
|---|---|---|---|
| 299 | The helicase-like transcription factor and its implication in cancer progression. **2008**, 65, 591-604 | | 43 |
| 298 | An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies. **2008**, 27, 2766-79 | | 220 |
| 297 | Analysis of the largest tandemly repeated DNA families in the human genome. **2008**, 9, 533 | | 106 |
| 296 | Epigenetic mechanisms of facioscapulohumeral muscular dystrophy. **2008**, 647, 94-102 | | 45 |
| 295 | Telomeric chromatin: roles in aging, cancer and hereditary disease. **2008**, 647, 86-93 | | 11 |
| 294 | First International "Institute of Myology Workshop" on Facioscapulohumeral Muscular Dystrophy, Paris, May 22, 2007. *Neuromuscular Disorders*, **2008**, 18, 514-8 | 2.9 | 1 |
| 293 | DUX4c, an FSHD candidate gene, interferes with myogenic regulators and abolishes myoblast differentiation. **2008**, 214, 87-96 | | 65 |
| 292 | A functional role for 4qA/B in the structural rearrangement of the 4q35 region and in the regulation of FRG1 and ANT1 in facioscapulohumeral dystrophy. *PLoS ONE*, **2008**, 3, e3389 | 3.7 | 38 |
| 291 | DUX4c is up-regulated in FSHD. It induces the MYF5 protein and human myoblast proliferation. *PLoS ONE*, **2009**, 4, e7482 | 3.7 | 43 |
| 290 | The D4Z4 macrosatellite repeat acts as a CTCF and A-type lamins-dependent insulator in facio-scapulo-humeral dystrophy. *PLoS Genetics*, **2009**, 5, e1000394 | 6 | 84 |
| 289 | Transcriptional regulation differs in affected facioscapulohumeral muscular dystrophy patients compared to asymptomatic related carriers. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 6220-5 | 11.5 | 38 |
| 288 | RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy. *Human Molecular Genetics*, **2009**, 18, 2414-30 | 5.6 | 170 |
| 287 | DNaseI hypersensitivity at gene-poor, FSH dystrophy-linked 4q35.2. *Nucleic Acids Research*, **2009**, 37, 7381-93 | 20.1 | 12 |
| 286 | Detailed cytogenetic and array analysis of pediatric primitive sarcomas reveals a recurrent CIC-DUX4 fusion gene event. **2009**, 195, 1-11 | | 81 |
| 285 | Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. **2009**, 30, 1449-59 | | 139 |
| 284 | Macrosatellite epigenetics: the two faces of DXZ4 and D4Z4. **2009**, 118, 675-81 | | 21 |
| 283 | Remodeling of the chromatin structure of the facioscapulohumeral muscular dystrophy (FSHD) locus and upregulation of FSHD-related gene 1 (FRG1) expression during human myogenic differentiation. **2009**, 7, 41 | | 72 |

| | | | |
|---|---|---|---|
| 282 | Hypermethylation of genomic 3.3-kb repeats is frequent event in HPV-positive cervical cancer. *BMC Medical Genomics*, **2009**, 2, 30 | 3.7 | 17 |
| 281 | Comprehensive expression analysis of FSHD candidate genes at the mRNA and protein level. **2009**, 17, 1615-24 | | 49 |
| 280 | Analysis of telomeric DNA: Current approaches and methods. *Russian Journal of Developmental Biology*, **2009**, 40, 125-144 | 0.8 | 4 |
| 279 | Therapy for neuromuscular disorders. **2009**, 19, 290-7 | | 26 |
| 278 | Pearls in the junk: dissecting the molecular pathogenesis of facioscapulohumeral muscular dystrophy. *Neuromuscular Disorders*, **2009**, 19, 17-20 | 2.9 | 28 |
| 277 | Cis-ruption mechanisms: disruption of cis-regulatory control as a cause of human genetic disease. **2009**, 8, 317-32 | | 56 |
| 276 | Current world literature. **2009**, 22, 554-61 | | |
| 275 | Facioscapulohumeral muscular dystrophy. **2009**, 22, 539-42 | | 32 |
| 274 | New Report Identifies Pathogen for Fascioscapulohumeral Dystrophy. **2010**, 10, 15 | | |
| 273 | A unifying genetic model for facioscapulohumeral muscular dystrophy. **2010**, 329, 1650-3 | | 504 |
| 272 | In junk we trust: repetitive DNA, epigenetics and facioscapulohumeral muscular dystrophy. **2010**, 2, 271-87 | | 24 |
| 271 | A family history of DUX4: phylogenetic analysis of DUXA, B, C and Duxbl reveals the ancestral DUX gene. **2010**, 10, 364 | | 68 |
| 270 | Expression, tandem repeat copy number variation and stability of four macrosatellite arrays in the human genome. **2010**, 11, 632 | | 33 |
| 269 | Myoblasts from affected and non-affected FSHD muscles exhibit morphological differentiation defects. **2010**, 14, 275-89 | | 90 |
| 268 | Genes, mutations, and human inherited disease at the dawn of the age of personalized genomics. **2010**, 31, 631-55 | | 138 |
| 267 | Characterization of genomic structures and expression profiles of three tandem repeats of a mouse double homeobox gene: Duxbl. **2010**, 239, 927-40 | | 21 |
| 266 | Analysis of allele-specific RNA transcription in FSHD by RNA-DNA FISH in single myonuclei. **2010**, 18, 448-56 | | 30 |
| 265 | Description of muscle disease □specific diseases. 205-229 | | 1 |

| | | | |
|---|---|---|---|
| 264 | Facioscapulohumeral dystrophy. 314-322 | | 1 |
| 263 | The cell biology of disease: FSHD: copy number variations on the theme of muscular dystrophy. **2010**, 191, 1049-60 | | 50 |
| 262 | FSHD: a repeat contraction disease finally ready to expand (our understanding of its pathogenesis). *PLoS Genetics*, **2010**, 6, e1001180 | 6 | 5 |
| 261 | Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. *PLoS Genetics*, **2010**, 6, e1001181 | 6 | 317 |
| 260 | Alternative splicing and muscular dystrophy. **2010**, 7, 441-52 | | 34 |
| 259 | Genetics. Exposing a DUX tale. **2010**, 329, 1607-8 | | 3 |
| 258 | Distrofia muscolare facio-scapolo-omerale. **2011**, 11, 1-11 | | |
| 257 | Establishment of clonal myogenic cell lines from severely affected dystrophic muscles - CDK4 maintains the myogenic population. *Skeletal Muscle*, **2011**, 1, 12 | 5.1 | 46 |
| 256 | Facioscapulohumeral dystrophy and scapuloperoneal syndromes. **2011**, 101, 167-80 | | 28 |
| 255 | Characterization of DXZ4 conservation in primates implies important functional roles for CTCF binding, array expression and tandem repeat organization on the X chromosome. **2011**, 12, R37 | | 21 |
| 254 | Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence. **2011**, 17, 252-8 | | 107 |
| 253 | Retinal vascular disease and the pathogenesis of facioscapulohumeral muscular dystrophy. A signalling message from Wnt?. *Neuromuscular Disorders*, **2011**, 21, 263-71 | 2.9 | 35 |
| 252 | The FSHD atrophic myotube phenotype is caused by DUX4 expression. *PLoS ONE*, **2011**, 6, e26820 | 3.7 | 121 |
| 251 | Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions. **2011**, 24, 423-8 | | 42 |
| 250 | Dystrophie musculaire facio-scapulo-humÉale. **2011**, 8, 1-11 | | |
| 249 | The KrÜppel-like factor 15 as a molecular link between myogenic factors and a chromosome 4q transcriptional enhancer implicated in facioscapulohumeral dystrophy. **2011**, 286, 44620-31 | | 20 |
| 248 | The muscular dystrophies: distinct pathogenic mechanisms invite novel therapeutic approaches. **2011**, 13, 199-207 | | 12 |
| 247 | Gene expression during normal and FSHD myogenesis. *BMC Medical Genomics*, **2011**, 4, 67 | 3.7 | 63 |

| | | | |
|---|---|---|---|
| 246 | DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo. **2011**, 69, 540-52 | | 166 |
| 245 | AAV6-mediated systemic shRNA delivery reverses disease in a mouse model of facioscapulohumeral muscular dystrophy. **2011**, 19, 2055-64 | | 39 |
| 244 | RNA interference improves myopathic phenotypes in mice over-expressing FSHD region gene 1 (FRG1). **2011**, 19, 2048-54 | | 35 |
| 243 | Distinct epigenomic features in end-stage failing human hearts. **2011**, 124, 2411-22 | | 196 |
| 242 | Developments in RNA splicing and disease. **2011**, 3, a000778 | | 67 |
| 241 | Immunodetection of human double homeobox 4. **2011**, 30, 125-30 | | 38 |
| 240 | Facioscapulohumeral muscular dystrophy: consequences of chromatin relaxation. **2012**, 25, 614-20 | | 37 |
| 239 | Patients with a phenotype consistent with facioscapulohumeral muscular dystrophy display genetic and epigenetic heterogeneity. *Journal of Medical Genetics*, **2012**, 49, 41-6 | 5.8 | 40 |
| 238 | De novo and inherited CNVs in MZ twin pairs selected for discordance and concordance on Attention Problems. **2012**, 20, 1037-43 | | 47 |
| 237 | Epigenetic alterations in muscular disorders. **2012**, 2012, 256892 | | 6 |
| 236 | Conditional over-expression of PITX1 causes skeletal muscle dystrophy in mice. **2012**, 1, 629-639 | | 39 |
| 235 | Transcriptional profiling in facioscapulohumeral muscular dystrophy to identify candidate biomarkers. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 16234-9 | 11.5 | 61 |
| 234 | Functional muscle impairment in facioscapulohumeral muscular dystrophy is correlated with oxidative stress and mitochondrial dysfunction. **2012**, 53, 1068-79 | | 73 |
| 233 | Generation of isogenic D4Z4 contracted and noncontracted immortal muscle cell clones from a mosaic patient: a cellular model for FSHD. **2012**, 181, 1387-401 | | 52 |
| 232 | Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. *Nature Genetics*, **2012**, 44, 1370-4 | 36.3 | 405 |
| 231 | Mutation spectrum and phenotypic manifestation in FSHD Greek patients. *Neuromuscular Disorders*, **2012**, 22, 339-49 | 2.9 | 34 |
| 230 | A unique library of myogenic cells from facioscapulohumeral muscular dystrophy subjects and unaffected relatives: family, disease and cell function. **2012**, 20, 404-10 | | 42 |
| 229 | Deciphering transcription dysregulation in FSH muscular dystrophy. **2012**, 57, 477-84 | | 5 |

| | | | |
|---|---|---|---|
| 228 | The CIC-DUX4 fusion transcript is present in a subgroup of pediatric primitive round cell sarcomas. **2012**, 43, 180-9 | | 131 |
| 227 | DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. **2012**, 22, 38-51 | | 295 |
| 226 | A long ncRNA links copy number variation to a polycomb/trithorax epigenetic switch in FSHD muscular dystrophy. **2012**, 149, 819-31 | | 290 |
| 225 | RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy. **2012**, 20, 1417-23 | | 82 |
| 224 | Facioscapulohumeral Muscular Dystrophy: Unraveling the Mysteries of a Complex Epigenetic Disease. **2012**, 969-977 | | 0 |
| 223 | Asymmetric bidirectional transcription from the FSHD-causing D4Z4 array modulates DUX4 production. *PLoS ONE*, **2012**, 7, e35532 | 3.7 | 18 |
| 222 | Different molecular signatures in magnetic resonance imaging-staged facioscapulohumeral muscular dystrophy muscles. *PLoS ONE*, **2012**, 7, e38779 | 3.7 | 80 |
| 221 | A repetitive elements perspective in Polycomb epigenetics. **2012**, 3, 199 | | 26 |
| 220 | The epigenetics of facioscapulohumeral muscular dystrophy. 347-361 | | 0 |
| 219 | Epigenetic modifications in cardiovascular disease. **2012**, 107, 245 | | 93 |
| 218 | Facioscapulohumeral muscular dystrophy (FSHD): an enigma unravelled?. **2012**, 131, 325-40 | | 61 |
| 217 | miR-411 is up-regulated in FSHD myoblasts and suppresses myogenic factors. *Orphanet Journal of Rare Diseases*, **2013**, 8, 55 | 4.2 | 33 |
| 216 | Kinetics and epigenetics of retroviral silencing in mouse embryonic stem cells defined by deletion of the D4Z4 element. **2013**, 21, 1536-50 | | 18 |
| 215 | [Facioscapulohumeral muscular dystrophy type 2]. **2013**, 169, 564-72 | | 1 |
| 214 | Facioscapulohumeral Dystrophy. **2013**, 288-297 | | 2 |
| 213 | The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1. **2013**, 93, 744-51 | | 126 |
| 212 | Pitx genes are redeployed in adult myogenesis where they can act to promote myogenic differentiation in muscle satellite cells. **2013**, 377, 293-304 | | 24 |
| 211 | [Clinical and molecular diagnosis of facioscapulohumeral dystrophy type 1 (FSHD1) in 2012]. **2013**, 169, 573-82 | | 1 |

| | | | |
|---|---|---|---|
| 210 | Exome sequencing identifies a novel SMCHD1 mutation in facioscapulohumeral muscular dystrophy 2. *Neuromuscular Disorders*, **2013**, 23, 975-80 | 2.9 | 26 |
| 209 | Muscular dystrophies. **2013**, 381, 845-60 | | 280 |
| 208 | DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?. **2013**, 17, 76-89 | | 90 |
| 207 | Expression of the human FSHD-linked DUX4 gene induces neurogenesis during differentiation of murine embryonic stem cells. **2013**, 22, 2440-8 | | 10 |
| 206 | The role of genetics in the establishment and maintenance of the epigenome. **2013**, 70, 1543-73 | | 47 |
| 205 | Telomere position effect regulates DUX4 in human facioscapulohumeral muscular dystrophy. **2013**, 20, 671-8 | | 74 |
| 204 | Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy. *Neuromuscular Disorders*, **2013**, 23, 306-12 | 2.9 | 31 |
| 203 | Deregulation of the protocadherin gene FAT1 alters muscle shapes: implications for the pathogenesis of facioscapulohumeral dystrophy. *PLoS Genetics*, **2013**, 9, e1003550 | 6 | 58 |
| 202 | Intrinsic epigenetic regulation of the D4Z4 macrosatellite repeat in a transgenic mouse model for FSHD. *PLoS Genetics*, **2013**, 9, e1003415 | 6 | 83 |
| 201 | Wnt/Ecatenin signaling suppresses DUX4 expression and prevents apoptosis of FSHD muscle cells. *Human Molecular Genetics*, **2013**, 22, 4661-72 | 5.6 | 75 |
| 200 | Defective regulation of microRNA target genes in myoblasts from facioscapulohumeral dystrophy patients. **2013**, 288, 34989-5002 | | 46 |
| 199 | A focal domain of extreme demethylation within D4Z4 in FSHD2. *Neurology*, **2013**, 80, 392-9 | 6.5 | 49 |
| 198 | Facioscapulohumeral muscular dystrophy: Are telomeres the end of the story?. **2013**, 1, e26142 | | 1 |
| 197 | Expression of DUX4 in zebrafish development recapitulates facioscapulohumeral muscular dystrophy. *Human Molecular Genetics*, **2013**, 22, 568-77 | 5.6 | 61 |
| 196 | Multiple protein domains contribute to nuclear import and cell toxicity of DUX4, a candidate pathogenic protein for facioscapulohumeral muscular dystrophy. *PLoS ONE*, **2013**, 8, e75614 | 3.7 | 16 |
| 195 | The "grep" command but not FusionMap, FusionFinder or ChimeraScan captures the CIC-DUX4 fusion gene from whole transcriptome sequencing data on a small round cell tumor with t(4;19)(q35;q13). *PLoS ONE*, **2014**, 9, e99439 | 3.7 | 41 |
| 194 | DNA methylation analysis of the macrosatellite repeat associated with FSHD muscular dystrophy at single nucleotide level. *PLoS ONE*, **2014**, 9, e115278 | 3.7 | 25 |
| 193 | Meeting Report: New Directions in the Biology and Disease of Skeletal Muscle 2014. *Journal of Neuromuscular Diseases*, **2014**, 1, 197-206 | 5 | 1 |

| | | | |
|---|---|---|---|
| 192 | Morpholino treatment improves muscle function and pathology of Pitx1 transgenic mice. **2014**, 22, 390-396 | | 16 |
| 191 | Dominant lethal pathologies in male mice engineered to contain an X-linked DUX4 transgene. *Cell Reports*, **2014**, 8, 1484-96 | 10.6 | 54 |
| 190 | Double homeobox gene, Duxbl, promotes myoblast proliferation and abolishes myoblast differentiation by blocking MyoD transactivation. **2014**, 358, 551-66 | | 7 |
| 189 | Satellite DNA and related diseases. **2014**, 30, 249-259 | | 5 |
| 188 | Dux4 induces cell cycle arrest at G1 phase through upregulation of p21 expression. **2014**, 446, 235-40 | | 34 |
| 187 | High-throughput screening identifies inhibitors of DUX4-induced myoblast toxicity. *Skeletal Muscle*, **2014**, 4, 4 | 5.1 | 48 |
| 186 | Subtelomeres. **2014**, | | 6 |
| 185 | DUX4 and DUX4 downstream target genes are expressed in fetal FSHD muscles. *Human Molecular Genetics*, **2014**, 23, 171-81 | 5.6 | 49 |
| 184 | Genetic and epigenetic characteristics of FSHD-associated 4q and 10q D4Z4 that are distinct from non-4q/10q D4Z4 homologs. **2014**, 35, 998-1010 | | 29 |
| 183 | Facioscapulohumeral dystrophy: the path to consensus on pathophysiology. *Skeletal Muscle*, **2014**, 4, 12 | 5.1 | 113 |
| 182 | Clinical trial preparedness in facioscapulohumeral dystrophy: outcome measures and patient access: 8-9 April 2013, Leiden, The Netherlands. *Neuromuscular Disorders*, **2014**, 24, 79-85 | 2.9 | 24 |
| 181 | Chromatin modifications remodel cardiac gene expression. **2014**, 103, 7-16 | | 42 |
| 180 | Expression of FSHD-related DUX4-FL alters proteostasis and induces TDP-43 aggregation. **2015**, 2, 151-66 | | 35 |
| 179 | DNA-binding sequence specificity of DUX4. *Skeletal Muscle*, **2016**, 6, 8 | 5.1 | 27 |
| 178 | Correlation between low FAT1 expression and early affected muscle in facioscapulohumeral muscular dystrophy. **2015**, 78, 387-400 | | 27 |
| 177 | Culture Conditions Affect Expression of DUX4 in FSHD Myoblasts. **2015**, 20, 8304-15 | | 13 |
| 176 | A muscle stem cell for every muscle: variability of satellite cell biology among different muscle groups. **2015**, 7, 190 | | 31 |
| 175 | FHL1 reduces dystrophy in transgenic mice overexpressing FSHD muscular dystrophy region gene 1 (FRG1). *PLoS ONE*, **2015**, 10, e0117665 | 3.7 | 7 |

| | | | |
|---|---|---|---|
| 174 | Aberrant splicing in transgenes containing introns, exons, and V5 epitopes: lessons from developing an FSHD mouse model expressing a D4Z4 repeat with flanking genomic sequences. *PLoS ONE*, **2015**, 10, e0118813 | 3.7 | 10 |
| 173 | Systemic Redox Biomarkers in Neurodegenerative Diseases. **2015**, 16, 46-70 | | 5 |
| 172 | Transcriptional Pathways Associated with Skeletal Muscle Changes after Spinal Cord Injury and Treadmill Locomotor Training. **2015**, 2015, 387090 | | 6 |
| 171 | Direct interplay between two candidate genes in FSHD muscular dystrophy. *Human Molecular Genetics*, **2015**, 24, 1256-66 | 5.6 | 20 |
| 170 | ZNF555 protein binds to transcriptional activator site of 4qA allele and ANT1: potential implication in Facioscapulohumeral dystrophy. *Nucleic Acids Research*, **2015**, 43, 8227-42 | 20.1 | 4 |
| 169 | Potential of antisense therapy for facioscapulohumeral muscular dystrophy. **2015**, 3, 1365-1374 | | 2 |
| 168 | Identification of variants in the 4q35 gene FAT1 in patients with a facioscapulohumeral dystrophy-like phenotype. **2015**, 36, 443-53 | | 29 |
| 167 | Catenin is central to DUX4-driven network rewiring in facioscapulohumeral muscular dystrophy. **2015**, 12, 20140797 | | 29 |
| 166 | Facioscapulohumeral Dystrophy. **2015**, 620-630 | | |
| 165 | Emerging preclinical animal models for FSHD. **2015**, 21, 295-306 | | 34 |
| 164 | SORBS2 transcription is activated by telomere position effect-over long distance upon telomere shortening in muscle cells from patients with facioscapulohumeral dystrophy. *Genome Research*, **2015**, 25, 1781-90 | 9.7 | 55 |
| 163 | Genetic and epigenetic contributors to FSHD. **2015**, 33, 56-61 | | 63 |
| 162 | Genomic Elements in Health, Disease and Evolution. **2015**, | | 3 |
| 161 | Structure and Functions of Telomeres in Organismal Homeostasis and Disease. **2015**, 247-283 | | |
| 160 | The Role of D4Z4-Encoded Proteins in the Osteogenic Differentiation of Mesenchymal Stromal Cells Isolated from Bone Marrow. **2015**, 24, 2674-86 | | 8 |
| 159 | Loss of epigenetic silencing of the DUX4 transcription factor gene in facioscapulohumeral muscular dystrophy. *Human Molecular Genetics*, **2015**, 24, R17-23 | 5.6 | 18 |
| 158 | Facioscapulohumeral muscular dystrophy. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2015**, 1852, 607-14 | 6.9 | 38 |
| 157 | Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease. **2015**, 22, 1463-82 | | 27 |

| | | | |
|---|---|---|---|
| 156 | Diagnostic approach for FSHD revisited: SMCHD1 mutations cause FSHD2 and act as modifiers of disease severity in FSHD1. **2015**, 23, 808-16 | | 69 |
| 155 | Identification of two novel SMCHD1 sequence variants in families with FSHD-like muscular dystrophy. **2015**, 23, 67-71 | | 16 |
| 154 | Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2. *Human Molecular Genetics*, **2015**, 24, 659-69 | 5.6 | 106 |
| 153 | Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy. **2016**, 5, | | 11 |
| 152 | PARP1 Differentially Interacts with Promoter region of Gene in FSHD Myoblasts. **2016**, 7, | | 8 |
| 151 | Epigenetics and Epigenomics in Human Health and Disease. **2016**, 51-74 | | |
| 150 | Dux4 controls migration of mesenchymal stem cells through the Cxcr4-Sdf1 axis. **2016**, 7, 65090-65108 | | 15 |
| 149 | Targeting mRNA for the treatment of facioscapulohumeral muscular dystrophy. **2016**, 5, 168-76 | | 6 |
| 148 | Homologous Transcription Factors DUX4 and DUX4c Associate with Cytoplasmic Proteins during Muscle Differentiation. *PLoS ONE*, **2016**, 11, e0146893 | 3.7 | 19 |
| 147 | Transgenic Drosophila for Investigating DUX4 and FRG1, Two Genes Associated with Facioscapulohumeral Muscular Dystrophy (FSHD). *PLoS ONE*, **2016**, 11, e0150938 | 3.7 | 11 |
| 146 | Influence of Repressive Histone and DNA Methylation upon D4Z4 Transcription in Non-Myogenic Cells. *PLoS ONE*, **2016**, 11, e0160022 | 3.7 | 36 |
| 145 | Nuclear bodies reorganize during myogenesis in vitro and are differentially disrupted by expression of FSHD-associated DUX4. *Skeletal Muscle*, **2016**, 6, 42 | 5.1 | 12 |
| 144 | DUX4 induces a transcriptome more characteristic of a less-differentiated cell state and inhibits myogenesis. **2016**, 129, 3816-3831 | | 50 |
| 143 | Polycomb repressive complex 1 provides a molecular explanation for repeat copy number dependency in FSHD muscular dystrophy. *Human Molecular Genetics*, **2017**, 26, 753-767 | 5.6 | 0 |
| 142 | Deciphering "B-others": Novel fusion genes driving B-cell acute lymphoblastic leukemia. **2016**, 8, 8-9 | | 3 |
| 141 | A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy. *Neuromuscular Disorders*, **2016**, 26, 844-852 | 2.9 | 23 |
| 140 | Mouse Dux is myotoxic and shares partial functional homology with its human paralog DUX4. *Human Molecular Genetics*, **2016**, 25, 4577-4589 | 5.6 | 30 |
| 139 | Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. *Nature Genetics*, **2016**, 48, 1481-1489 | 36.3 | 145 |

| | | | |
|---|---|---|---|
| 138 | Transcriptional Inhibitors Identified in a 160,000-Compound Small-Molecule DUX4 Viability Screen. **2016**, 21, 680-8 | | 11 |
| 137 | Antisense targeting of 3Rend elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach. *Human Molecular Genetics*, **2016**, 25, 1468-78 | 5.6 | 55 |
| 136 | Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. *Nature Genetics*, **2016**, 48, 569-74 | 36.3 | 141 |
| 135 | DUX4 recruits p300/CBP through its C-terminus and induces global H3K27 acetylation changes. *Nucleic Acids Research*, **2016**, 44, 5161-73 | 20.1 | 84 |
| 134 | Antisense oligonucleotide development for the treatment of muscular dystrophies. **2016**, 4, 139-152 | | 16 |
| 133 | Large family cohorts of lymphoblastoid cells provide a new cellular model for investigating facioscapulohumeral muscular dystrophy. *Neuromuscular Disorders*, **2017**, 27, 221-238 | 2.9 | 16 |
| 132 | Emerging roles of macrosatellite repeats in genome organization and disease development. **2017**, 12, 515-526 | | 22 |
| 131 | Long-term regulation of gene expression in muscle cells by systemically delivered siRNA. **2017**, 256, 101-113 | | 4 |
| 130 | Primary CIC-DUX4 round cell sarcoma of the kidney: A treatment-refractory tumor with poor outcome. **2017**, 213, 154-160 | | 5 |
| 129 | A double-edged sword: The world according to Capicua in cancer. **2017**, 108, 2319-2325 | | 16 |
| 128 | Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model. *Nature Communications*, **2017**, 8, 550 | 17.4 | 50 |
| 127 | Facioscapulohumeral Muscular Dystrophy. **2017**, 7, 1229-1279 | | 29 |
| 126 | The DUX4 homeodomains mediate inhibition of myogenesis and are functionally exchangeable with the Pax7 homeodomain. **2017**, 130, 3685-3697 | | 33 |
| 125 | p53-independent DUX4 pathology in cell and animal models of facioscapulohumeral muscular dystrophy. *DMM Disease Models and Mechanisms*, **2017**, 10, 1211-1216 | 4.1 | 18 |
| 124 | Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines. *Scientific Reports*, **2017**, 7, 4712 | 4.9 | 29 |
| 123 | SMCHD1 regulates a limited set of gene clusters on autosomal chromosomes. *Skeletal Muscle*, **2017** , 7, 12 | 5.1 | 18 |
| 122 | Analyzing Copy Number Variation Using Pulsed-Field Gel Electrophoresis: Providing a Genetic Diagnosis for FSHD1. **2017**, 1492, 107-125 | | 5 |
| 121 | PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle. *Nature Communications*, **2017**, 8, 2152 | 17.4 | 49 |

| | | | |
|---|---|---|---|
| 120 | Clinical and genetic characteristics and diagnostic features of Landouzy-Dejerine facioscapulohumeral muscular dystrophy. **2017**, 53, 640-650 | | 0 |
| 119 | Pitx2 in Embryonic and Adult Myogenesis. **2017**, 5, 46 | | 27 |
| 118 | Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD). *Genes*, **2017**, 8, | 4.2 | 38 |
| 117 | Are Antioxidants a Potential Therapy for FSHD? A Review of the Literature. **2017**, 2017, 7020295 | | 15 |
| 116 | Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD. **2018**, 8, 121-130 | | 32 |
| 115 | Muscle Microdialysis to Investigate Inflammatory Biomarkers in Facioscapulohumeral Muscular Dystrophy. **2018**, 55, 2959-2966 | | 16 |
| 114 | Deep characterization of a common D4Z4 variant identifies biallelic DUX4 expression as a modifier for disease penetrance in FSHD2. **2018**, 26, 94-106 | | 15 |
| 113 | Nablus syndrome: Easy to diagnose yet difficult to solve. **2018**, 178, 447-457 | | 2 |
| 112 | Low level DUX4 expression disrupts myogenesis through deregulation of myogenic gene expression. *Scientific Reports*, **2018**, 8, 16957 | 4.9 | 16 |
| 111 | Advances in the Understanding of Skeletal Myopathies from Zebrafish Models. **2018**, 151-183 | | 1 |
| 110 | Zebrafish, Medaka, and Other Small Fishes. **2018**, | | 2 |
| 109 | Phenotype-genotype relations in facioscapulohumeral muscular dystrophy type 1. *Clinical Genetics*, **2018**, 94, 521-527 | 4 | 14 |
| 108 | Cis D4Z4 repeat duplications associated with facioscapulohumeral muscular dystrophy type 2. *Human Molecular Genetics*, **2018**, 27, 3488-3497 | 5.6 | 11 |
| 107 | Myoediting: Toward Prevention of Muscular Dystrophy by Therapeutic Genome Editing. **2018**, 98, 1205-1240 | | 18 |
| 106 | Targeting the Polyadenylation Signal of Pre-mRNA: A New Gene Silencing Approach for Facioscapulohumeral Dystrophy. *International Journal of Molecular Sciences*, **2018**, 19, | 6.3 | 8 |
| 105 | Muscle Involvement and Restricted Disorders. **2018**, 922-970.e15 | | 2 |
| 104 | Overexpression of the double homeodomain protein DUX4c interferes with myofibrillogenesis and induces clustering of myonuclei. *Skeletal Muscle*, **2018**, 8, 2 | 5.1 | 9 |
| 103 | A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy. *PLoS ONE*, **2018**, 13, e0192657 | 3.7 | 38 |

| | | | |
|---|---|---|---|
| 102 | Muscle xenografts reproduce key molecular features of facioscapulohumeral muscular dystrophy. **2019**, 320, 113011 | | 16 |
| 101 | SMCHD1 mutation spectrum for facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS) reveals disease-specific localisation of variants in the ATPase domain. *Journal of Medical Genetics*, **2019**, 56, 693-700 | 5.8 | 14 |
| 100 | Intronic variants in FSHD: testing the potential for CRISPR-Cas9 genome editing. *Journal of Medical Genetics*, **2019**, 56, 828-837 | 5.8 | 15 |
| 99 | Omics Approaches to Understanding Muscle Biology. **2019**, | | 2 |
| 98 | 240th ENMC workshop: The involvement of skeletal muscle stem cells in the pathology of muscular dystrophies 25-27 January 2019, Hoofddorp, The Netherlands. *Neuromuscular Disorders*, **2019**, 29, 704-715 | 2.9 | 2 |
| 97 | RNAscope in situ hybridization-based method for detecting RNA expression in vitro. *Rna*, **2019**, 25, 1211-1217 | 5.1 | 10 |
| 96 | DUX4 Pathological Expression: Causes and Consequences in Cancer. *Trends in Cancer*, **2019**, 5, 268-271 | 12.5 | 9 |
| 95 | 4q-D4Z4 chromatin architecture regulates the transcription of muscle atrophic genes in facioscapulohumeral muscular dystrophy. *Genome Research*, **2019**, 29, 883-895 | 9.7 | 10 |
| 94 | The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy. *Annual Review of Genomics and Human Genetics*, **2019**, 20, 265-291 | 9.7 | 29 |
| 93 | Molecular Basis of Muscle Disease. **2019**, 13-39 | | |
| 92 | Genotype-phenotype correlations in FSHD. *BMC Medical Genomics*, **2019**, 12, 43 | 3.7 | 3 |
| 91 | PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level. *Human Molecular Genetics*, **2019**, 28, 2224-2236 | 5.6 | 21 |
| 90 | Identifying the RNA signatures of coronary artery disease from combined lncRNA and mRNA expression profiles. *Genomics*, **2020**, 112, 4945-4958 | 4.3 | 7 |
| 89 | Multi-Omics Identifies Circulating miRNA and Protein Biomarkers for Facioscapulohumeral Dystrophy. *Journal of Personalized Medicine*, **2020**, 10, | 3.6 | 4 |
| 88 | Cellular and animal models for facioscapulohumeral muscular dystrophy. *DMM Disease Models and Mechanisms*, **2020**, 13, | 4.1 | 2 |
| 87 | Skeletal muscle regeneration in facioscapulohumeral muscular dystrophy is correlated with pathological severity. *Human Molecular Genetics*, **2020**, 29, 2746-2760 | 5.6 | 9 |
| 86 | Expression in FSHD Muscles: Focus on Its mRNA Regulation. *Journal of Personalized Medicine*, **2020**, 10, | 3.6 | 5 |
| 85 | Therapeutic Strategies Targeting DUX4 in FSHD. *Journal of Clinical Medicine*, **2020**, 9, | 5.1 | 7 |

| | | | |
|---|---|---|---|
| 84 | Expression of Dux family genes in early preimplantation embryos. *Scientific Reports*, **2020**, 10, 19396 | 4.9 | 4 |
| 83 | Current Genetic Survey and Potential Gene-Targeting Therapeutics for Neuromuscular Diseases. *International Journal of Molecular Sciences*, **2020**, 21, | 6.3 | 4 |
| 82 | Yeast mismatch repair components are required for stable inheritance of gene silencing. *PLoS Genetics*, **2020**, 16, e1008798 | 6 | 0 |
| 81 | Emerging Roles of RNA 3Rend Cleavage and Polyadenylation in Pathogenesis, Diagnosis and Therapy of Human Disorders. *Biomolecules*, **2020**, 10, | 5.9 | 21 |
| 80 | DUX4, a Zygotic Genome Activator, Is Involved in Oncogenesis and Genetic Diseases. *Russian Journal of Developmental Biology*, **2020**, 51, 176-182 | 0.8 | 1 |
| 79 | G-quadruplex ligands mediate downregulation of DUX4 expression. *Nucleic Acids Research*, **2020**, 48, 4179-4194 | 20.1 | 9 |
| 78 | Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy. *Science Translational Medicine*, **2020**, 12, | 17.5 | 24 |
| 77 | Does DNA Methylation Matter in FSHD?. *Genes*, **2020**, 11, | 4.2 | 8 |
| 76 | Antibodies Against Three Novel Peptides in Early Axial Spondyloarthritis Patients From Two Independent Cohorts. *Arthritis and Rheumatology*, **2020**, 72, 2094-2105 | 9.5 | 3 |
| 75 | DNA aptamers against the DUX4 protein reveal novel therapeutic implications for FSHD. *FASEB Journal*, **2020**, 34, 4573-4590 | 0.9 | 10 |
| 74 | Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy. *Clinical Genetics*, **2020**, 97, 799-814 | 4 | 16 |
| 73 | DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy. *International Journal of Molecular Sciences*, **2020**, 21, | 6.3 | 22 |
| 72 | DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation. *Human Molecular Genetics*, **2020**, 29, 2285-2299 | 5.6 | 6 |
| 71 | Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity. *Skeletal Muscle*, **2020**, 10, 8 | 5.1 | 18 |
| 70 | Chromosome 10q-linked FSHD identifies as principal disease gene. *Journal of Medical Genetics*, **2021**, | 5.8 | 6 |
| 69 | Systemic antisense therapeutics inhibiting DUX4 expression improves muscle function in an FSHD mouse model. | | 1 |
| 68 | Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update. *Orphanet Journal of Rare Diseases*, **2021**, 16, 129 | 4.2 | 7 |
| 67 | Designed U7 snRNAs inhibit˝expression and improve FSHD-associated outcomes in˝overexpressing cells and FSHD patient myotubes. *Molecular Therapy - Nucleic Acids*, **2021**, 23, 476-486 | 10.7 | 6 |

| | | | |
|---|---|---|---|
| 66 | Genetic Approaches for the Treatment of Facioscapulohumeral Muscular Dystrophy. *Frontiers in Pharmacology*, **2021**, 12, 642858 | 5.6 | 2 |
| 65 | Herpesviral induction of germline transcription factor DUX4 is critical for viral gene expression. | | 2 |
| 64 | FSHD1 Diagnosis in a Russian Population Using a qPCR-Based Approach. *Diagnostics*, **2021**, 11, | 3.8 | |
| 63 | Current Therapeutic Approaches in FSHD. *Journal of Neuromuscular Diseases*, **2021**, 8, 441-451 | 5 | 5 |
| 62 | Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model. *Human Molecular Genetics*, **2021**, 30, 1398-1412 | 5.6 | 4 |
| 61 | DUX4 induces a homogeneous sequence of molecular changes, culminating in the activation of a stem-cell-like transcriptional network and induction of apoptosis in somatic cells. | | 0 |
| 60 | Losing DNA methylation at repetitive elements and breaking bad. *Epigenetics and Chromatin*, **2021**, 14, 25 | 5.8 | 10 |
| 59 | CRISPR mediated targeting of DUX4 distal regulatory element represses DUX4 target genes dysregulated in Facioscapulohumeral muscular dystrophy. *Scientific Reports*, **2021**, 11, 12598 | 4.9 | 3 |
| 58 | Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7. *EMBO Molecular Medicine*, **2021**, 13, e13695 | 12 | 9 |
| 57 | The asymmetric Pitx2 regulates intestinal muscular-lacteal development and protects against fatty liver disease. | | |
| 56 | Hypoxia and Hypoxia-Inducible Factor Signaling in Muscular Dystrophies: Cause and Consequences. *International Journal of Molecular Sciences*, **2021**, 22, | 6.3 | 5 |
| 55 | Analysis of genes regulated by DUX4 via oxidative stress reveals potential therapeutic targets for treatment of facioscapulohumeral dystrophy. *Redox Biology*, **2021**, 43, 102008 | 11.3 | 3 |
| 54 | p53 convergently activates Dux/DUX4 in embryonic stem cells and in facioscapulohumeral muscular dystrophy cell models. *Nature Genetics*, **2021**, 53, 1207-1220 | 36.3 | 11 |
| 53 | Precise Epigenetic Analysis Using Targeted Bisulfite Genomic Sequencing Distinguishes FSHD1, FSHD2, and Healthy Subjects. *Diagnostics*, **2021**, 11, | 3.8 | 0 |
| 52 | High resolution breakpoint junction mapping of proximally extended D4Z4 deletions in FSHD1 reveals evidence for a founder effect. *Human Molecular Genetics*, **2021**, | 5.6 | 0 |
| 51 | The CAM Model for Sarcoma and Its Potential Use for Precision Medicine. *Cells*, **2021**, 10, | 7.9 | 1 |
| 50 | Crystallin in Mouse Skeletal Muscle Promotes a Shift from Glycolytic toward Oxidative Metabolism. *Current Research in Physiology*, **2021**, 4, 47-59 | 1.8 | 1 |
| 49 | RNAi Therapy for Dominant Muscular Dystrophies and Other Myopathies. **2010**, 99-115 | | 6 |

| | | | |
|---|---|---|---|
| 48 | A genome-wide CRISPR/Cas phenotypic screen for modulators of DUX4 cytotoxicity reveals screen complications. | | 0 |
| 47 | Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity. | | 1 |
| 46 | Single-nucleus RNA-seq identifies divergent populations of FSHD2 myotube nuclei. | | 1 |
| 45 | AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD. *JCI Insight*, **2018**, 3, | 9.9 | 38 |
| 44 | Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by antagonizing DUX4 activity. *Journal of Clinical Investigation*, **2017**, 127, 1531-1545 | 15.9 | 31 |
| 43 | Complex evolution of a Y-chromosomal double homeobox 4 (DUX4)-related gene family in hominoids. *PLoS ONE*, **2009**, 4, e5288 | 3.7 | 7 |
| 42 | Biphasic myopathic phenotype of mouse DUX, an ORF within conserved FSHD-related repeats. *PLoS ONE*, **2009**, 4, e7003 | 3.7 | 47 |
| 41 | Variation in array size, monomer composition and expression of the macrosatellite DXZ4. *PLoS ONE* , **2011**, 6, e18969 | 3.7 | 18 |
| 40 | Expression profiling of FSHD-1 and FSHD-2 cells during myogenic differentiation evidences common and distinctive gene dysregulation patterns. *PLoS ONE*, **2011**, 6, e20966 | 3.7 | 35 |
| 39 | DNA replication timing is maintained genome-wide in primary human myoblasts independent of D4Z4 contraction in FSH muscular dystrophy. *PLoS ONE*, **2011**, 6, e27413 | 3.7 | 19 |
| 38 | FSHD myotubes with different phenotypes exhibit distinct proteomes. *PLoS ONE*, **2012**, 7, e51865 | 3.7 | 20 |
| 37 | DUX4 differentially regulates transcriptomes of human rhabdomyosarcoma and mouse C2C12 cells. *PLoS ONE*, **2013**, 8, e64691 | 3.7 | 47 |
| 36 | Facioscapulohumeral Muscular Dystrophy: More Complex than it Appears. *Current Molecular Medicine*, **2014**, 14, 1052-1068 | 2.5 | 22 |
| 35 | Gene Editing Targeting the DUX4 Polyadenylation Signal: A Therapy for FSHD?. *Journal of Personalized Medicine*, **2020**, 11, | 3.6 | 3 |
| 34 | Modeling diseases of noncoding unstable repeat expansions using mutant pluripotent stem cells. *World Journal of Stem Cells*, **2015**, 7, 823-38 | 5.6 | 6 |
| 33 | Inactivation of the CIC-DUX4 oncogene through P300/CBP inhibition, a therapeutic approach for CIC-DUX4 sarcoma. *Oncogenesis*, **2021**, 10, 68 | 6.6 | 0 |
| 32 | DNA crosslinking and recombination-activating genes 1/2 (RAG1/2) are required for oncogenic splicing in acute lymphoblastic leukemia. *Cancer Communications*, **2021**, 41, 1116-1136 | 9.4 | 1 |
| 31 | Facioscapulohumeral Muscular Dystrophy. | | |

| | | | |
|---|---|---|---|
| 30 | FSHD: A Subtelomere-Associated Disease. **2014**, 165-185 | | |
| 29 | [illegible] *Russian Journal of Genetics*, **2017**, 651-662 | 0.8 | |
| 28 | Molecular signatures of differential responses to exercise trainings during rehabilitation. **2017**, 2, | | 2 |
| 27 | p53 is not necessary for DUX4 pathology. | | |
| 26 | Facioscapulohumeral Muscular Dystrophy: Genetics. 1-13 | | 2 |
| 25 | Transcriptomic Approaches for Muscle Biology and Disorders. **2019**, 79-107 | | |
| 24 | 4q-D4Z4 chromatin architecture regulates the transcription of muscle atrophic genes in FSHD. | | |
| 23 | Lymphocytes contribute to DUX4 target genes in FSHD muscle biopsies. | | 1 |
| 22 | Muscular Dystrophy- Facioscapulohumeral Dystrophy - A Rare Autosomal Dominant Disorder. *Journal of Evolution of Medical and Dental Sciences*, **2020**, 9, 1616-1618 | 0.1 | |
| 21 | Testing the effects of FSHD candidate gene expression in vertebrate muscle development. *International Journal of Clinical and Experimental Pathology*, **2010**, 3, 386-400 | 1.4 | 67 |
| 20 | Nucleolar-based Dux repression is essential for 2-cell stage exit. | | 0 |
| 19 | The asymmetric Pitx2 gene regulates gut muscular-lacteal development and protects against fatty liver disease. *Cell Reports*, **2021**, 37, 110030 | 10.6 | 0 |
| 18 | Improving molecular and histopathology in diaphragm muscle of the double transgenic ACTA1-MCM/FLExDUX4 mouse model of FSHD with systemic antisense therapy.. *Human Gene Therapy*, **2022**, | 4.8 | 1 |
| 17 | Zygotic gene activation in mice: profile and regulation.. *Journal of Reproduction and Development*, **2022**, | 2.1 | 1 |
| 16 | Cross-sectional, Neuromuscular Phenotyping Study of Arhinia Patients With Variants.. *Neurology*, **2022**, | 6.5 | 1 |
| 15 | The evolution of DUX4 gene regulation and its implication for facioscapulohumeral muscular dystrophy.. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2022**, 1868, 166367 | 6.9 | 1 |
| 14 | Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy. *Nature Communications*, **2021**, 12, 7128 | 17.4 | 3 |
| 13 | Outcome Measures in Facioscapulohumeral Muscular Dystrophy Clinical Trials.. *Cells*, **2022**, 11, | 7.9 | 2 |

| | | | |
|---|---|---|---|
| 12 | Considerations and practical implications of performing a phenotypic CRISPR/Cas survival screen.. *PLoS ONE*, **2022**, 17, e0263262 | 3.7 | 1 |
| 11 | Nucleolar-based repression is essential for embryonic two-cell stage exit.. *Genes and Development*, **2022**, | 12.6 | 1 |
| 10 | Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit DUX4 Expression. *Biomedicines*, **2022**, 10, 1623 | 4.8 | 0 |
| 9 | ANT1 overexpression models: Some similarities with facioscapulohumeral muscular dystrophy. **2022**, 56, 102450 | | |
| 8 | Methylation of the 4q35 D4Z4 repeat defines disease status in facioscapulohumeral muscular dystrophy. | | 0 |
| 7 | Update on the Molecular Aspects and Methods Underlying the Complex Architecture of FSHD. **2022**, 11, 2687 | | 0 |
| 6 | Antagonism Between DUX4 and DUX4c Highlights a Pathomechanism Operating Through Catenin in Facioscapulohumeral Muscular Dystrophy. 10, | | 0 |
| 5 | A circulating biomarker of facioscapulohumeral muscular dystrophy clinical severity, valid in skeletal muscle and blood. | | 0 |
| 4 | Facioscapulohumeral muscular dystrophy: the road to targeted therapies. | | 0 |
| 3 | The double homeodomain protein DUX4c is associated with regenerating muscle fibers and RNA-binding proteins. **2023**, 13, | | 0 |
| 2 | Nutritional Status of Patients with Facioscapulohumeral Muscular Dystrophy. **2023**, 15, 1673 | | 0 |
| 1 | 268th ENCM workshop - Genetic diagnosis, clinical classification, outcome measures, and biomarkers in Facioscapulohumeral Muscular Dystrophy (FSHD): relevance for clinical trials. **2023**, | | 0 |